Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU/India joint inspections

This article was originally published in The Gold Sheet

Executive Summary

There may soon be joint inspections of drug manufacturing sites conducted by EU and Indian inspectors under the framework of the European Pharmacopoeia procedure of certification under the terms of a recent agreement. Signatories included the European Directorate for the Quality of Medicines and Healthcare (EDQM), the Ministry of Health of India, and the Indian Pharmacopoeia Committee (IPC). Under the terms of the agreement, drugs manufactured and approved for sale in either market may be subject to expedited approval. Officials announced that the other potential areas of collaboration include the development of harmonized chemical and herbals monographs, common training activities in the pharmacopoeial field, scientific cooperation by inviting pharmaceutical scientists to the EDQM, and observer status for the European Pharmacopoeia to the Indian Pharmacopoeia Commission. EDQM Director Susanne Keitel and EDQM official Dr. Claude Coune of EDQM met with Dr. Anbumani Ramadoss, India's Minister of Health and Family Welfare, Dr. Surinder Singh, drugs controller general of India and Dr. G.N. Singh, the incoming scientific director of the Indian Pharmacopoeia (IPC) in New Delhi and IPC's headquarters in Ghaziabad, India to finalize the agreement
UsernamePublicRestriction

Register

PS000246

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel